These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35110537)

  • 21. Arginine refolds, stabilizes, and restores function of mutant pVHL proteins in animal model of the VHL cancer syndrome.
    Shmueli MD; Levy-Kanfo L; Haj E; Schoenfeld AR; Gazit E; Segal D
    Oncogene; 2019 Feb; 38(7):1038-1049. PubMed ID: 30194449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SHARPIN regulates the development of clear cell renal cell carcinoma by promoting von Hippel-Lindau protein ubiquitination and degradation.
    Yin R; Liu S
    Cancer Sci; 2021 Oct; 112(10):4100-4111. PubMed ID: 34339558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
    Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-ΔC in clear cell Renal Cell Carcinoma patients.
    Fabbri L; Dufies M; Lacas-Gervais S; Gardie B; Gad-Lapiteau S; Parola J; Nottet N; Meyenberg Cunha de Padua M; Contenti J; Borchiellini D; Ferrero JM; Leclercq NR; Ambrosetti D; Mograbi B; Richard S; Viotti J; Chamorey E; Sadaghianloo N; Rouleau M; Craigen WJ; Mari B; Clavel S; Pagès G; Pouysségur J; Bost F; Mazure NM
    Theranostics; 2020; 10(6):2696-2713. PubMed ID: 32194829
    [No Abstract]   [Full Text] [Related]  

  • 26. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
    Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
    Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene.
    Baldewijns MM; van Vlodrop IJ; Smits KM; Vermeulen PB; Van den Eynden GG; Schot F; Roskams T; van Poppel H; van Engeland M; de Bruïne AP
    Cell Oncol; 2009; 31(5):371-82. PubMed ID: 19759417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
    Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
    Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of pVHL as a novel substrate for Aurora-A in clear cell renal cell carcinoma (ccRCC).
    Martin B; Chesnel F; Delcros JG; Jouan F; Couturier A; Dugay F; Le Goff X; Patard JJ; Fergelot P; Vigneau C; Rioux-Leclerq N; Arlot-Bonnemains Y
    PLoS One; 2013; 8(6):e67071. PubMed ID: 23785518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIF-2α expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma.
    Bacigalupa ZA; Arner EN; Vlach LM; Wolf MM; Brown WA; Krystofiak ES; Ye X; Hongo RA; Landis M; Amason EK; Beckermann KE; Rathmell WK; Rathmell JC
    J Clin Invest; 2024 Jun; 134(12):. PubMed ID: 38941296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prefoldin complex stabilizes the von Hippel-Lindau protein against aggregation and degradation.
    Chesnel F; Couturier A; Alusse A; Gagné JP; Poirier GG; Jean D; Boisvert FM; Hascoet P; Paillard L; Arlot-Bonnemains Y; Le Goff X
    PLoS Genet; 2020 Nov; 16(11):e1009183. PubMed ID: 33137104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer.
    Chakraborty AA
    Semin Cancer Biol; 2020 Dec; 67(Pt 2):34-42. PubMed ID: 32209418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma.
    Kong HS; Lee S; Beebe K; Scroggins B; Gupta G; Lee MJ; Jung YJ; Trepel J; Neckers L
    Mol Pharmacol; 2010 Dec; 78(6):1072-8. PubMed ID: 20813864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
    Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
    Anal Cell Pathol (Amst); 2010; 33(3):121-32. PubMed ID: 20978319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
    Jung YS; Lee SJ; Yoon MH; Ha NC; Park BJ
    Cell Cycle; 2012 Dec; 11(23):4462-73. PubMed ID: 23159849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.
    Sorrell AD; Lee S; Stolle C; Ellenhorn J; Grix A; Kaelin WG; Weitzel JN
    Clin Genet; 2011 Jun; 79(6):539-45. PubMed ID: 20560986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.
    Gao W; Li W; Xiao T; Liu XS; Kaelin WG
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1027-1032. PubMed ID: 28082722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
    Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
    Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology.
    Shirole NH; Kaelin WG
    Hematol Oncol Clin North Am; 2023 Oct; 37(5):809-825. PubMed ID: 37270382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis.
    Forman JR; Worth CL; Bickerton GR; Eisen TG; Blundell TL
    Proteins; 2009 Oct; 77(1):84-96. PubMed ID: 19408298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.